[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100595173":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":23,"centralContacts":27,"locations":33,"responsibleParty":57,"collaborators":31,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":31,"eligibilityCriteria":67,"healthyVolunteers":63,"sex":68,"minAge":69,"maxAge":31,"enrollmentInfo":70,"targetDuration":31,"studyType":73,"phases":74,"briefSummary":76,"conditions":77,"keywords":31,"overallStatus":36,"whyStopped":31,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"Children's Hospital Medical Center, Cincinnati","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"liraglutide treatment","EXPERIMENTAL","After baseline evaluation of enteroendocrine levels and metabolism, study participants will be prescribed liraglutide. Titration of liraglutide will be as follows: 1) Starting dose of liraglutide 0.6 mg daily for 1 week, 2) Increase to liraglutide 1.2 mg daily for 1 week, and 3) Maintain at final dose of liraglutide 1.8 mg daily. If study participants are unable to tolerate liragultide 1.8 mg daily due to side effects for 1 week, then will decrease back to liraglutide 1.2 mg daily.",[13],"Drug: Liraglutide",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Liraglutide","Liraglutide will be prescribed following FDA approved packet insert for type 2 diabetes in our test population.",[9],[21,22],"Victoza","Saxenda",[24],{"name":25,"affiliation":5,"role":26},"Mansa Krishnamurthy, M.D.","PRINCIPAL_INVESTIGATOR",[28],{"name":25,"role":29,"phone":30,"phoneExt":31,"email":32},"CONTACT","513-636-4744",null,"mansa.krishnamurthy@cchmc.org",[34],{"facility":35,"status":36,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Cincinnati Children's Hospital Medical Center","RECRUITING","Cincinnati","Ohio","45229","United States","US",{"type":43,"coordinates":44},"Point",[45,46],-84.51439,39.12711,{"lat":46,"lon":45},[49,53,55],{"name":50,"role":29,"phone":51,"phoneExt":31,"email":52},"Lily Deng","513-636-0002","lily.deng@cchmc.org",{"name":54,"role":26,"phone":31,"phoneExt":31,"email":31},"Mansa Krishnamurthy",{"name":50,"role":56,"phone":31,"phoneExt":31,"email":31},"SUB_INVESTIGATOR",{"type":58,"investigatorFullName":59,"investigatorTitle":60,"investigatorAffiliation":5,"oldNameTitle":31,"oldOrganization":31},"SPONSOR_INVESTIGATOR","Mansa","ASSISTANT PROFESSOR","100595173","phase-2-liraglutide-treatment-in-patients-with-maturity-onset-diabetes-of-the-young-mody-100595173",false,"NCT07029009","Liraglutide Treatment in Patients With Maturity-onset Diabetes of the Young (MODY)","Investigating Enteroendocrine Dysfunction, Metabolism, and Response to Liraglutide in Patients With Maturity-onset Diabetes of the Young (MODY)","Inclusion Criteria:\n\n* Diagnosis of MODY via genetic testing\n* HgbA1c \\>6.5%\n\nExclusion Criteria:\n\n* History of anaphylaxis to GLP-1 receptor agonists\n* Already taking GLP-1 receptor agonists\n* on medications within the stimulant class\n* have had bariatric surgery\n* personal or family history of cancer, especially medullary thyroid cancer\n* personal history of pancreatitis or pathogenic variants associated with increased risk of pancreatitis\n* known active kidney disease\n* severe hypoglycemia (glucose \\\u003C 50 mg\u002FdL) within 3 months of study enrollment\n* HbA1c \\> 10.0%\n* episode of diabetic ketoacidosis (DKA) in the past 3 months\n* are currently pregnant\n* BMI \\\u003C 18.5 kg\u002Fm2 and pediatric patients with BMI \\\u003C 5th percentile","ALL","10 Years",{"count":71,"type":72},50,"ESTIMATED","INTERVENTIONAL",[75],"PHASE2","The reason for this research study is to better understand the use of liraglutide, a commonly prescribed Type 2 diabetes medication, in patients with a diagnosis of maturity-onset diabetes of the young (MODY).\n\nThe investigators are interested in better understanding the way that this drug affects the metabolism and hormone levels of a person with MODY. Many people with MODY report having gastrointestinal (GI) issues such as an upset stomach. Investigators also are interested in finding out if this drug will help with GI issues.\n\nIf liraglutide does help with this symptom of MODY, the investigators want to know why this happens. If this drug is effective for participants, the investigators will use participants cells to make human induced pluripotent stem cell (iPSC). This means that the investigators will use participant cells to create what are called stem cells, which are cells in the body that are able to be told what their job is. Investigators will use these cells to see what happens in gastrointestinal (GI) tract.",[78],"Maturity Onset Diabetes of the Young","2025-12-12",{"date":81,"type":82},"2025-12-17","ACTUAL",{"date":84,"type":82},"2025-05-08",{"date":86,"type":72},"2027-01",{"name":59,"class":6},1]